These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2140314)

  • 1. [ACE-inhibitors: physiologic premises and pharmacologic profiles].
    Marino A; Schettini G; Florio T; Ventra C
    Clin Ter; 1990 Feb; 132(4):267-76. PubMed ID: 2140314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects.
    Falkenhahn M; Gohlke P; Paul M; Stoll M; Unger T
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S6-13. PubMed ID: 7898096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE inhibitors: review of four new agents.
    Binder SB
    Am Fam Physician; 1993 Oct; 48(5):851-7. PubMed ID: 8213415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of ACE-inhibition in the therapy of chronic heart insufficiency].
    Drexler H; Just H
    Wien Med Wochenschr; 1990 Jan; 140(1-2):40-5. PubMed ID: 2137955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotection by angiotensin-converting enzyme (ACE) inhibitors.
    Juggi JS; Koenig-Berard E; Van Gilst WH
    Can J Cardiol; 1993 May; 9(4):336-52. PubMed ID: 8513428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renin-angiotensin system as a target for therapeutic intervention.
    Swales JD
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S1-5. PubMed ID: 7898088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers].
    Pichler M; Klein W; Huber K; Pachinger O
    Wien Med Wochenschr; 1996; 146(11):228-31. PubMed ID: 8928520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical pharmacology of angiotensin II antagonists].
    Arabidze GG; Novikova LS
    Farmakol Toksikol; 1990; 53(2):80-6. PubMed ID: 2369961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rational therapy of heart failure].
    Werner MG; Schmieder RE
    Z Kardiol; 1993; 82 Suppl 4():7-16. PubMed ID: 8147063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current indications for ACE inhibitors and HOPE for the future.
    Burch S; Ou N
    Am J Manag Care; 2002 May; 8(5):478-90; quiz 491-3. PubMed ID: 12019599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects?
    Frank GJ
    J Hypertens Suppl; 1989 Sep; 7(5):S17-22. PubMed ID: 2553900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?
    Sambhi MP; Gavras H; Robertson JI; Smith WM
    West J Med; 1993 Mar; 158(3):286-94. PubMed ID: 8460511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses.
    Dzau VJ; Creager MA
    Cardiol Clin; 1989 Feb; 7(1):119-30. PubMed ID: 2650868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C; Cosentino E; De Sanctis D
    Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Renal side effects of angiotensin converting enzyme inhibitors].
    Schmidt A; Mayer G
    Wien Med Wochenschr; 1996; 146(16):454-6. PubMed ID: 9036683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of ACE inhibitors and angiotensin receptor blockers in the treatment and prevention of chronic heart failure].
    Kárpáti P
    Orv Hetil; 2005 May; 146(18):827-31. PubMed ID: 15926627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure.
    Banerjee A; Talreja A; Sonnenblick EH; LeJemtel TH
    Mt Sinai J Med; 2003 Sep; 70(4):225-31. PubMed ID: 12968195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.